KDR and cholangiocarcinoma: A phase II study of sorafenib, a kinase inhibitor of VEGFR2/3, PEGFR, and RAF, evaluating the safety and efficacy of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma was terminated because it did not result in objective responses (ORR:0%) (18).